Imaging Properties and Tumor Targeting of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients

Background: Gastrin-releasing peptide receptors (GRPRs) are molecular imaging targets in multiple malignancies. Recently, NeoBOMB1, a 68Ga-labelled antagonist to GRPRs, was developed for PET. Here we report the outcome of a Phase I/IIa clinical trial (EudraCT 2016-002053-38) describing diagnostic properties and covariates influencing uptake of 68Ga-NeoBOMB1 in oligometastatic gastrointestinal stromal tumor (GIST) patients. Methods: Nine patients with advanced GIST using PET/CT (computed tomography) were included. After kit-based 68Ga-NeoBOMB1 preparation with a licensed 68Ge/68Ga generator, 3 MBq/kg body weight were injected intravenously. PET/CT included dynamic and static PET scans 5, 12 and 18 min and 1, 2, and 3–4 h post injection (first six patients) and static PET scans 2 and 3–4 h post injection (last three participants). Tumor targeting was assessed on a per-lesion and per-patient basis. Results: Six patients showed visible radiotracer uptake in at least one tumor lesion. Seventeen out of 37 tumor lesions exhibited significant 68Ga-NeoBOMB1 uptake (median SUVmax 11.8 [range 2.8–51.1] 2 h p.i. and 13.2 [range 2.5–53.8] 3–4 h p.i) and improved lesion-to-background contrast over time. Five lesions (13.5%) were identified only by 68Ga-NeoBOMB1-PET, with no correlation on contrast-enhanced CT. Three patients showed no radiotracer accumulation in any lesions. Tracer uptake correlated with male sex (p < 0.0001), higher body mass index (p = 0.007), and non-necrotic lesion appearance (p = 0.018). There was no association with whole-lesion contrast enhancement, hepatic localization, mutational status, or disease duration. Conclusions: 68Ga-NeoBOMB1-PET exhibits variable tumor uptake in advanced-stage GIST patients, correlating with lesion vitality based on CT contrast uptake, opening the possibility of a theragnostic approach in selected cases.

[1]  S. Schoenberg,et al.  MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients , 2020, The Journal of Nuclear Medicine.

[2]  V. Tolmachev,et al.  Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist 177Lu‐DOTAGA‐PEG2‐RM26 , 2019, International journal of cancer.

[3]  E. Krenning,et al.  Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results , 2017, The Journal of Nuclear Medicine.

[4]  E. Wardelmann,et al.  Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. Søreide,et al.  Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. , 2016, Cancer epidemiology.

[6]  T. Taguchi,et al.  Targeting Gastrointestinal Stromal Tumor with 68Ga-Labeled Peptides: An In Vitro Study on Gastrointestinal Stromal Tumor-Cell Lines. , 2016, Cancer biotherapy & radiopharmaceuticals.

[7]  H. Joensuu,et al.  Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. , 2015, European journal of cancer.

[8]  W. Hohenberger,et al.  Management of liver metastases of gastrointestinal stromal tumors (GIST). , 2015, Annals of hepatology.

[9]  R. Maki,et al.  GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Zhongqiang Zhang,et al.  Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials , 2014, Drug design, development and therapy.

[11]  N. Avril,et al.  GRP Receptor Imaging of Prostate Cancer Using [99mTc]Demobesin 4: a First-in-Man Study , 2014, Molecular Imaging and Biology.

[12]  F. van Coevorden,et al.  Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[13]  C. Fletcher The evolving classification of soft tissue tumours – an update based on the new 2013 WHO classification , 2014, Histopathology.

[14]  S. Rosati,et al.  Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients: a first-in-man study. , 2013, Nuclear medicine and biology.

[15]  I. Jambor,et al.  In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548 , 2013, Clinical Cancer Research.

[16]  I. Jambor,et al.  Plasma Pharmacokinetics, Whole-Body Distribution, Metabolism, and Radiation Dosimetry of 68Ga Bombesin Antagonist BAY 86-7548 in Healthy Men , 2013, The Journal of Nuclear Medicine.

[17]  L. Strauss,et al.  Correlation of the Ga-68-Bombesin Analog Ga-68-BZH3 with Receptors Expression in Gliomas as Measured by Quantitative Dynamic Positron Emission Tomography (dPET) and Gene Arrays , 2011, Molecular Imaging and Biology.

[18]  Kirsten Schmieder,et al.  Pharmacokinetic Studies of 68Ga-Labeled Bombesin (68Ga-BZH3) and F-18 FDG PET in Patients With Recurrent Gliomas and Comparison to Grading: Preliminary Results , 2011, Clinical nuclear medicine.

[19]  W. Schima,et al.  Bildgebende Diagnostik bei GIST , 2009, Wiener Medizinische Wochenschrift.

[20]  J. Lasota,et al.  Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours , 2008, Histopathology.

[21]  C. Santos-Cuevas,et al.  Targeted imaging of gastrin-releasing peptide receptors with 99mTc-EDDA/HYNIC-[Lys3]-bombesin: biokinetics and dosimetry in women , 2008, Nuclear medicine communications.

[22]  Haesun Choi,et al.  Response evaluation of gastrointestinal stromal tumors. , 2008, The oncologist.

[23]  P. Woll,et al.  Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate , 2008, Therapeutics and clinical risk management.

[24]  Peter Hohenberger,et al.  68Ga-Labeled Bombesin Studies in Patients with Gastrointestinal Stromal Tumors: Comparison with 18F-FDG , 2007, Journal of Nuclear Medicine.

[25]  C. Charnsangavej,et al.  Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[26]  L. Mazzucchelli,et al.  High expression of peptide receptors as a novel target in gastrointestinal stromal tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  S. Hirota,et al.  Gastrointestinal stromal tumors (GIST): A model for molecule‐based diagnosis and treatment of solid tumors , 2003, Cancer science.

[28]  J. Lasota,et al.  Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.